Unidad de Ensayos Clínicos
Agencia Española del Medicamento y Productos Sanitarios (AEMPS)
Parque Empresarial Las Mercedes, Edificio 8
C. Campezo, 1
28922 Madrid

European Medicines Agency (EMA)
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Subject	To state reasons for the trial premature interruption
Study Title	Adequate Duration of Antibiotic Treatment in Community-acquired Pneumonia With High Risk Class and Adequate Initial Clinical Response
Protocol code	NACATB
EudraCT Number	2017-001406-15
Product	Moxifloxacino (400 mg)
Sponsor	Fundació Clínic per la Recerca Biomèdica- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Trial end	23rd May 2020

21st October 2026

Dear sir/madam,

The trial was a multicentre study conducted in Spain.

This trial was approved by the Spanish authorities but never started.

This study was a Low Intervention Trial.

The active sites were:

- Hospital Clínic de Barcelona, C/ Villarroel 170, 08036 (Barcelona)
- Hospital de Mataró, Carretera de Cirera 230, 08304 (Mataró)
- Universidad de Sevilla
- H. Universitario La Fe, Avenida Fernando Abril Martorell, 46026 (Valencia)
- Hospital de Galdakao-Unsasolo, Labeaga Auzoa, 48960 (Galdácano, Basque Country)

Harmonised Protocol (version 1.0, 07th April 2018):

Member State	Date of approval		
	National Competent Authority	Ethics Committee	Name of Ethics Committee
SPAIN	26-Jul-2018	15-Jun-2018	CEIm Hospital Clinic de Barcelona

Declaration

The sponsor, Fundació de Recerca Clínic Barcelona- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), hereby declares that the clinical trial with EudraCT Number 2017-001406-15 ended prematurely on 23rd May 2020. The clinical trial was not initiated as the participation of the additional planned centers could not be secured.

Please do not hesitate in contacting us should you need further information.

Yours faithfully,

Sara Campos
Application Submitter CTU CLINIC